# Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients

> **NCT00884273** · PHASE3 · COMPLETED · sponsor: **Ferring Pharmaceuticals** · enrollment: 182 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Degarelix
- **DRUG:** Goserelin
- **DRUG:** Bicalutamide

## Key facts

- **NCT ID:** NCT00884273
- **Lead sponsor:** Ferring Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 182 (ACTUAL)
- **Last updated:** 2013-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00884273

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00884273, "Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients". Retrieved via AI Analytics 2026-08-02 from https://api.ai-analytics.org/clinical/NCT00884273. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*